HeartWare International — Corporate Update (August 2008)
19 slides from HeartWare International's corporate update, Aug 12, 2008
Slide 1: HeartWare Limited Corporate Update August 2008
HeartWare Limited (ASX:HTW) » Corporate Update August 2008 » Doug Godshall CEO
Slide 2: Disclosures
Disclosures Not an Offer for Securities This Presentation does not constitute nor does it contain an offer or invitation to buy or subscribe for securities in HeartWare Limited (the Company) or an inducement to make an offer or invitation with respect to those securities. Relevant Law The Company's
Slide 3: Overview
Overview HeartWare is developing the world's smallest implantable pumps for the treatment of advanced heart failure Heart failure is a leading cause of death in the developed world and represents a significant emerging medical device market The HeartWare(r) LVAD System is demonstrating promising cli
Slide 4: Heart Failure
Heart Failure A degenerative and terminal disease Affects over 20 million people globally (5+ million in the US) 1 million new cases diagnosed every year 300,000 deaths per year in the US At least 1 million patients in NYHA Class IV, the end-stage of the disease In the US, heart failure represents M
Slide 5: LVADs are the only viable option for most
LVAD's are the only viable option for most Heart transplantation is a proven therapy, but availability is severely limited Fewer than 4,000 donor hearts annually; (~2,200 per year in the US) Many patients ineligible for transplantation Alternative therapies not delivering on initial promise Drugs &
Slide 6: VADs: a year overnight success
VAD's: a 25 year overnight success Source: Canaccord Adams Aug. 1, 2008 report Historic compound growth rate >12% pa despite no new technology 2008 inflection in market growth HeartMate II - the first new pump approved since 1998 Early adoption rate signaling strong demand Waiting list expanded '06
Slide 7: Opportunity for significant long term growth
Opportunity for significant long term growth 100,000 + Destination Therapy / "Bridge to Decision" Estimated 50,000+ patients per year in US alone BTT market potential ~4,000-5000 patients per year Potential VAD Patients per Year Market Drivers New devices - HMII, HeartWare Improving long term outcom
Slide 8: Pericardial placement offers potential benefits
Pericardial placement - Offers potential benefits Pericardial Potential Benefits: No abdominal surgery No pump pocket Reduced Recovery time Reduced procedural invasiveness and complexity Shorter pump implant time HeartWare LVAD Caution - Investigational Device, Limited by United States Law to Invest
Slide 9: The HeartWare Left Ventricular Assist System
The HeartWare(c) Left Ventricular Assist System Miniaturized implantable blood pump (50cc / 145g) The only centrifugal pump designed to be implanted in the chest, directly adjacent to the heart Designed to produce up to 10 liters of flow Only one moving part Hybrid magnetic / hydrodynamic suspension
Slide 10: International clinical trial progress to date
International clinical trial progress to date 41 patients enrolled to date Extension approved to allow up to 50 patients Primary endpoint is survival to 180 days or transplant Submission of Technical Dossier expected Q3 2008, CE mark anticipated Q4 2008
Slide 11: Promising early data
Dr George Wieselthaler, Principal Investigator at Vienna General Hospital, with three of his HeartWare patients 41 patients enrolled Cumulative support - 9,730 days (~27 yrs) Average support - 243 days per patient >91% survival (of first 29 patients, 27 have successfully passed trial endpoint) Total
Slide 12: Outcomes at Days
Outcomes at 180 Days At 180 days: Survival - 91% Transplant- 10% Recovery - 0% Death - 9% Presented by G Wieselthaler, MD at the ISHLT Annual Meeting, Boston, MA, April 12, 2008 Data from first 23 patients enrolled in HeartWare clinical trial
Slide 13: US clinical trial - imminent start
US clinical trial - imminent start Received conditional approval for BTT protocol Allowed to commence pivotol trial 150 patients at a maximum 28 centers Utilizing NIH funded control arm (Intermacs Registry) Immediate patient discharge permitted Site training underway Expect first patient August / Se
Slide 14: Product pipeline - pump miniaturization
Product pipeline - pump miniaturization Procedure Surgical Minimally Invasive Catheter Delivery System Flow 10 L/min 7 L/min 3 L/min Patient Class Late Class IV Class III & IV Class III Treatable Pop. 100,000 350,000 1,000,000 Current status: IDE Preclinical studies Prototype and exploratory HVADTM
Slide 15: MVAD showing its potential
MVAD showing its potential Developing implant techniques that avoid sternotomy Extremely encouraging preclinical results Goals are Small incision Decrease complications Increase number of patients who can benefit Will select "winner" in 2008 Full project kick off in 2009
Slide 16: Transcutaneous Energy Transfer showing significant progress
Transcutaneous Energy Transfer showing significant progress Designed to enable transfer of energy and information across the skin Replaces driveline cable and eliminates risk of driveline complications Designed to enable patient to be un- tethered from the charging system for extended periods Pre-cl
Slide 17: Upcoming milestones
Upcoming milestones Milestone Timing Status Extension of International Trial to allow additional implants Q4 2007 Conditional IDE Approval Q2 2008 Commencement of US Clinical Trial Q3 2008 On Target First Revenue Q3 2008 On Target Submission of Technical Dossier to Competent Authority Q3 2008 On Tar
Slide 18: Financial snapshot ($AU)
Financial snapshot ($AU) Cash on hand $42.6M (31 July) Burn rate $2-2.5M per month First revenue Anticipated Q3 2008 Shares on issue 310M Market Cap $165M Number of employees 102 Top 20 shareholders > 75% of shares US Ownership > 80%
Slide 19: Summary
Summary Heart Failure is a disease of epidemic proportions The LVAD market is growing and poised for rapid acceleration HeartWare is well positioned to benefit from market growth now and will be the primary driver of dramatic growth in the future